Clinical Trial Update: Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials

View source ↗

Summary

Expanded Access Program for patients at risk for catheter-related bloodstream infections who are not eligible for DefenCath clinical trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catheter-related Bloodstream Infection

Drugs mentioned

• DEFENCATH (taurolidine and heparin)

Snippet

Sponsor: CorMedix | Conditions: Catheter-related Bloodstream Infection | Status: AVAILABLE